AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Endologix, Inc. to Present at the Stifel Healthcare Conference

November 11, 2019

IRVINE, Calif.--(BUSINESS WIRE)--Nov 11, 2019--

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m. ET on Tuesday, November 19, 2019 in New York, NY.

A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.endologix.com and will be available for replay following the event.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. For more information, visit www.endologix.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005551/en/

CONTACT: Investor:

Endologix, Inc.

Vaseem Mahboob, CFO

(949) 595-7200

KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SURGERY MEDICAL DEVICES HEALTH CARDIOLOGY MEDICAL SUPPLIES

SOURCE: Endologix, Inc.

Copyright Business Wire 2019.

PUB: 11/11/2019 04:01 PM/DISC: 11/11/2019 04:01 PM

http://www.businesswire.com/news/home/20191111005551/en